Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,967.38
(
1.18%
)
US TECH 100
25,149.55
(
0.02%
)
Dow Jones
48,535.99
(
0.66%
)
Brent Oil
92.74
(
-2.86%
)
Bitcoin
73,900.92
(
-0.41%
)
News Focus
News Focus
Post# of 257406
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

acgood

Send PM Follow Ignore
Followers 17
Posts 1093
Boards Moderated 0
Alias Born 05/12/2007

acgood

Re: oc631 post# 134723

Tuesday, 01/10/2012 9:13:39 AM

Tuesday, January 10, 2012 9:13:39 AM

Post# of 257406
I don't know if or when it will change, but RNAi technology is not being valued hardly at all anymore (pharma went down that road once). It is more likely that market will start to value RNAi-based drugs with actual clinical data, particularly (IMO) in the current rare diseases "rally"

Any comments here may have previously been disseminated on Twitter @BioDueDiligence or at www.biotechduediligence.com

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today